MTL Cannabis Past Earnings Performance
Past criteria checks 3/6
MTL Cannabis's earnings have been declining at an average annual rate of -1.2%, while the Pharmaceuticals industry saw earnings growing at 59.3% annually. Revenues have been growing at an average rate of 46.4% per year. MTL Cannabis's return on equity is 16.7%, and it has net margins of 3.8%.
Key information
-1.2%
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 46.4% |
| Return on equity | 16.7% |
| Net Margin | 3.8% |
| Last Earnings Update | 31 Mar 2024 |
Revenue & Expenses Breakdown
How MTL Cannabis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 65 | 2 | 18 | 0 |
| 31 Dec 23 | 59 | 1 | 15 | 0 |
| 30 Sep 23 | 47 | 0 | 12 | 0 |
| 30 Jun 23 | 32 | -3 | 9 | 0 |
| 31 Mar 23 | 25 | -2 | 8 | 0 |
| 31 Dec 22 | 22 | -5 | 10 | 0 |
| 31 Mar 22 | 22 | 2 | 8 | 0 |
| 31 Mar 21 | 13 | 1 | 3 | 0 |
Quality Earnings: MTLC has high quality earnings.
Growing Profit Margin: MTLC became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MTLC has become profitable over the past 5 years.
Accelerating Growth: MTLC has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: MTLC has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (11.7%).
Return on Equity
High ROE: MTLC's Return on Equity (16.7%) is considered low.